Menstrual Period Pain: Evidence-Based Causes, Red Flags, and Modern Treatments for Dysmenorrhea

Dysmenorrhea refers to painful menstrual periods, a common gynecologic condition that can range from mild cramping to disabling pelvic pain. It is typically divided into two categories: primary dysmenorrhea and secondary dysmenorrhea. Primary dysmenorrhea occurs without an underlying pelvic pathology and usually begins in adolescence, often within 1–2 years after menarche. Secondary dysmenorrhea results from identifiable disorders such as endometriosis, adenomyosis, fibroids, pelvic inflammatory disease, or ovarian cysts. Clinically, dysmenorrhea is important not only because it affects quality of life—school/work impairment, reduced physical activity, and mood disruption—but also because persistent or severe symptoms can signal an underlying disease requiring targeted evaluation.

The predominant mechanism behind primary dysmenorrhea involves increased uterine prostaglandin synthesis during menstruation. Prostaglandins, particularly prostaglandin F2α and prostaglandin E2, promote uterine smooth muscle contraction and vascular changes that can produce ischemia and cramping pain. A functional imbalance between prostaglandin production and clearance, along with increased sensitivity of uterine nerves, contributes to symptom severity. Risk factors include early age at menarche, heavy menstrual bleeding, smoking, low body mass index, nulliparity, and a family history of dysmenorrhea. Psychological and neurologic factors also modulate pain perception: stress, catastrophizing, sleep disruption, and comorbid anxiety or depression can amplify the experience of visceral pain.

Secondary dysmenorrhea often reflects chronic inflammatory and structural pathology. Endometriosis, for example, involves ectopic endometrial tissue that responds to hormonal cycling, leading to inflammatory mediator release, adhesions, and nociceptive sensitization. Adenomyosis causes ectopic endometrial glands within the myometrium, producing uterine enlargement and myometrial dysfunction. Fibroids can contribute via distorted uterine anatomy and increased bleeding. Pelvic inflammatory disease and certain infectious etiologies can cause pain associated with cervical or uterine inflammation.

A practical clinical approach begins with history: onset and pattern of pain (cyclicity, timing relative to menses), associated symptoms (heavy bleeding, dyspareunia, bowel or urinary pain), response to prior analgesics, and progression over time. Warning signs—often termed red flags—include new-onset severe dysmenorrhea after years of previously mild symptoms, pain that fails to respond to standard therapy, progressive worsening, intermenstrual pain, abnormal uterine bleeding, fever or systemic symptoms, infertility, postcoital bleeding, or severe dyspareunia. These features raise concern for secondary causes and warrant prompt gynecologic assessment.

Treatment is stepwise and evidence-based. First-line therapy for primary dysmenorrhea is NSAIDs (nonsteroidal anti-inflammatory drugs) because they inhibit cyclooxygenase enzymes and reduce prostaglandin synthesis. Optimal effectiveness is typically achieved by starting NSAIDs at the onset of symptoms or—where feasible—about 1 day before expected menses, continuing for several days through peak cramping. Examples include ibuprofen, naproxen, and mefenamic acid, though drug choice should consider contraindications such as peptic ulcer disease, renal impairment, anticoagulant use, and NSAID allergy.

If NSAIDs are insufficient, hormonal options can reduce menstrual bleeding and prostaglandin burden. Combined oral contraceptives, progestin-only methods, and levonorgestrel-releasing intrauterine systems can suppress ovulation and/or endometrial proliferation, thereby decreasing cyclic pain. For suspected endometriosis, hormonal suppression is commonly used alongside diagnostic imaging and, in select cases, surgical evaluation. Nonpharmacologic strategies—heat therapy, regular exercise, adequate sleep, and pelvic floor physiotherapy—can complement medical treatment. Given the role of central sensitization, cognitive-behavioral therapy and pain education may help patients reduce catastrophizing and improve coping.

In refractory cases, referral to a specialist is appropriate. Further evaluation may include pelvic ultrasound for structural causes, pregnancy testing when indicated, STI testing if risk factors exist, and consideration of pelvic MRI or endometriosis-focused assessment. The overarching goal is to relieve pain while addressing the underlying pathology when present.

Finally, dysmenorrhea intersects with mental health through the bidirectional relationship between chronic pain and affective disorders. Persistent pain can worsen anxiety, depressive symptoms, and sleep quality; conversely, heightened stress can increase pain sensitivity. Therefore, care should integrate both somatic and psychosocial dimensions, ensuring that pain is taken seriously, accurately characterized, and treated with a personalized, multimodal plan.

Source: @AnOffTopicTopic